Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Completion of the simvastatin intervention with at least 85% compliance
研究概览
简要总结
This is a single arm pilot trial to evaluate the feasibility of using a simvastatin intervention, and to evaluate its effects on cancer progression, among 20 patients with platinum-sensitive ovarian cancer, treated with carboplatin and liposomal doxorubicin at Cedars-Sinai Medical Center.
详细描述
This is a pilot study of statin therapy to examine the feasibility of simvastatin use to reduce disease progression in 20 patients with platinum-sensitive ovarian cancer at Cedars-Sinai Medical Center. This study will focus on patients with recurrent platinum sensitive ovarian cancer to increase the likelihood that this population will experience recurrent disease during the 6-month intervention and follow-up. In addition, this population of patients has a narrow range of standard of care carboplatin doublet combinations that are prescribed, enabling the investigators to create a more homogenous study population. Given their high risk of developing recurrent disease, women with platinum sensitive ovarian cancer, have the potential to derive the maximum benefit from an intervention that could delay disease progression and enhance survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Recurrent platinum sensitive ovarian cancer, all histologies (serous, endometrioid, mucinous, clear cell). Platinum sensitivity defined as ≥ 6 months since last platinum treatment.
- •No contraindication to carboplatin and/or liposomal doxorubicin or simvastatin.
排除标准
- •Prior or current use of any statin medication
- •Current systemic use of medications known to interact with statins
- •Current use of any other investigational agents
- •Liver disease, active cirrhosis
- •Uncontrolled intercurrent illness
- •History of chronic myopathy
- •Prior cancer other than ovarian cancer or non-melanomatous skin cancers
- •Known active infection with HIV
- •Current excessive alcohol consumption (average alcohol consumption of more than 5 drinks per day)
- •Prior exposure to doxorubicin or liposomal doxorubicin
- •Hemoglobin A1C >8.0%
研究组 & 干预措施
Simvastatin
干预措施: Simvastatin 40mg (Drug)
结局指标
主要结局
Completion of the simvastatin intervention with at least 85% compliance
时间窗: From Cycle 1 Day 1 until Cycle 6 Day 28 (each cycle is 28 days)
Percentage of patients who complete the simvastatin intervention with at least 85% compliance during Carboplatin and Doxil chemotherapy.
次要结局
- Response by CA125(From baseline until 12 months)
- Progression-free survival(From baseline until 12 months)
研究者
Marc Goodman
Oncologist
Cedars-Sinai Medical Center